Leukemia

Leukemia

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

34 Clinical Trials
Leukemia NA Accepting Patients
nct/study# NCT03258931 / ARO-021

Phase III Randomized Study Of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy And Consolidation Therapy In Actively Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia

Learn More
Leukemia Phase III Accepting Patients
nct/study# NCT02631070 / ACE-536-MDS-002

A Phase 3, Open-Label, Randomized Study To Compare The Efficacy And Safety Of Luspatercept (ACE-536) Versus Epoetin Alfa For The Treatment Of Anemia Due To IPSS-R Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes (MDS) In ESA Naïve Subjects Who Require Red Blood Cell Transfusions

Learn More
Leukemia Phase I Active
nct/study# NA / M20-866

A Phase 1b Dose Escalation Study Of Lemzoparlimab (TJ011133) In Combination With Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS Azacitidine And/Or Venetoclax In Subjects With Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS

Learn More
Leukemia NA Accepting Patients
nct/study# NCT01688011 / AZA-MDS-006

Connect MDS And AML: The Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukemia (AML) Disease Registry

Learn More
Leukemia Phase I/II Active
nct/study# NA / AT148002

A Phase 1/2 Study Of Alx148 In Combination With Azacitidine In Patients With Higher Risk Mds

Learn More
Leukemia NA Accepting Patients
nct/study# NA / EIND143853

Emergency IND For Midostaurin Liquid E-IND143853

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.